Successful Treatment with Mepolizumab for Coronary Spastic Angina Associated with Eosinophilic Granulomatosis with Polyangiitis

Intern Med. 2023;62(16):2389-2393. doi: 10.2169/internalmedicine.0930-22. Epub 2023 Aug 15.

Abstract

A 46-year-old man with a history of bronchial asthma and chronic sinusitis presented to our hospital with chest pain. We suspected angina evoked by epicardial coronary spasm and performed an ergonovine provocation test to diagnose coronary spastic angina (CSA). The patient also met the diagnostic criteria for eosinophilic granulomatosis with polyangiitis (EGPA) and was treated with 60 mg prednisolone (PSL) for EGPA-associated CSA. After PSL administration, eosinophils decreased, and angina attacks disappeared. However, when PSL was tapered to 12.5 mg, chest pain recurred. We administered mepolizumab subcutaneously and chest pain disappeared. Additional mepolizumab may be effective for EGPA with CSA.

Keywords: EGPA; bronchial asthma; coronary spastic angina; eosinophilia; mepolizumab.

Publication types

  • Case Reports

MeSH terms

  • Angina Pectoris / complications
  • Angina Pectoris / drug therapy
  • Chest Pain
  • Churg-Strauss Syndrome* / complications
  • Churg-Strauss Syndrome* / drug therapy
  • Granulomatosis with Polyangiitis* / complications
  • Granulomatosis with Polyangiitis* / drug therapy
  • Humans
  • Male
  • Middle Aged
  • Muscle Spasticity
  • Prednisolone / therapeutic use

Substances

  • mepolizumab
  • Prednisolone